2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113407B
    D-Fructose-6-phosphate disodium hydrate 918149-30-1 98%
    D-Fructose 6-phosphate disodium hydrate is an endogenous metabolite. D-Fructose 6-phosphate disodium hydrate can be obtained by hydrolysis of Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate disodium hydrate is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose-6-phosphate disodium hydrate can be used to detect glucosamine-6-phosphate synthase and TAL activities. D-Fructose 6-phosphate disodium hydrate can be used to study Lewy body dementia.
    D-Fructose-6-phosphate disodium hydrate
  • HY-118806A
    AC-42 hydrochloride 447407-36-5 98.42%
    AC-42 hydrochloride is the hydrochloride salt form of AC-42 (HY-118806). AC-42 hydrochloride is an allosteric agonist for muscarinic M1 receptor with EC50s of 805 nM and 220 nM for human wild-type and Y381A mutated M1 receptors, respectively. AC-42 hydrochloride stimulates the inositol phosphate (IP)-accumulation and calcium mobilization in CHO cells.
    AC-42 hydrochloride
  • HY-122489A
    (S)-Laudanosine 2688-77-9 99.95%
    (S)-Laudanosine is an alkaloid that can be found in poppies and is the S-enantiomer of Laudanosine. Laudanosine acts on the central nervous system and cardiovascular system, inhibiting low-affinity GABA receptors with an IC50 value of 10 μM, and can cause seizures, hypotension, and bradycardia. Additionally, Laudanosine exerts analgesic effects by competitively binding to the opioid Mu-1 receptor (Ki = 2.7 μM).
    (S)-Laudanosine
  • HY-123037R
    Triadimefon (Standard) 43121-43-3 98.05%
    Triadimefon (Standard) is the analytical standard of Triadimefon (HY-123037). This product is intended for research and analytical applications. Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of AKT1 and ERK1/2. Triadimefon significantly increases pAMPK levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory.
    Triadimefon (Standard)
  • HY-123689S
    Samidorphan-d4 98%
    Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo.
    Samidorphan-d4
  • HY-12515AR
    Nicardipine hydrochloride (Standard) 54527-84-3 99.65%
    Nicardipine (hydrochloride) (Standard) is the analytical standard of Nicardipine (hydrochloride). This product is intended for research and analytical applications. Nicardipine hydrochloride (YC-93) is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure.
    Nicardipine hydrochloride (Standard)
  • HY-12715S1
    Yohimbine-d3 133146-00-6 99.36%
    Yohimbine-d3 is the deuterium labeled Yohimbine (HY-12715).
    Yohimbine-d3
  • HY-132428S
    O-Desmethyl Tramadol-d6 873928-73-5 98%
    O-Desmethyl Tramadol-d6 is the deuterium labeled O-Desmethyl Tramadol. O-Desmethyl Tramadol is a primary active metabolite of Tramadol. O-Desmethyl Tramadol is mainly responsible for its μ-opioid receptor-related analgesic effect. Tramadol is metabolized to O-Demethyltramadol mainly by the cytochrome P450 (CYP) 2D6 enzyme.
    O-Desmethyl Tramadol-d6
  • HY-132580C
    Tofersen scrambled control
    Tofersen scrambled control is a scrambled control antisense oligonucleotide of Tofersen (HY-132580) with a scrambled sequence in the target binding region.
    Tofersen scrambled control
  • HY-132581E
    Scrambled Tadnersen
    Scrambled Tadnersen is the Negative Control of Tadnersen sodium (HY-132581A). Tadnersen sodium, an antisense oligonucleotide (ASO), selectively targets C9ORF72 transcript variants 1 and 3 that carry the expansion.
    Scrambled Tadnersen
  • HY-135407S
    N-Desethyl Oxybutynin-d5 hydrochloride 1173018-49-9 99.36%
    N-Desethyl Oxybutynin-d5 (hydrochloride) is deuterium labeled N-Desethyl Oxybutynin hydrochloride. N-Desethyl Oxybutynin is the the active metabolite Oxybutynin. Oxybutynin is an anticholinergic agent that inhibits voltage-dependent K+ channels.
    N-Desethyl Oxybutynin-d5 hydrochloride
  • HY-145603S
    Vanzacaftor-d4 98%
    Vanzacaftor-d4 (VX-121-d4) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases.
    Vanzacaftor-d4
  • HY-148349A
    (2R,2R)-PF-07258669 2755890-68-5 99.64%
    (2R,2R)-PF-07258669 is a MC4R (melanocortin 4 receptor) antagonist. (2R,2R)-PF-07258669 can be used in the study of regulating appetite and energy expenditure.
    (2R,2R)-PF-07258669
  • HY-150964S
    S-Adenosyl-L-methionine-d3 methylbenzenesulfonate 98%
    S-Adenosyl-L-methionine-d3 (S-Adenosyl methionine-d3) methylbenzenesulfonate is the deuterium labeled S-Adenosyl-L-methionine methylbenzenesulfonate. S-Adenosyl-L-methionine (S-Adenosyl methionine) is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research.
    S-Adenosyl-L-methionine-d3 methylbenzenesulfonate
  • HY-151481A
    β-FXR antagonist 1 2295804-92-9 99.80%
    β-FXR antagonist 1 (C 12), an isomer of FXR antagonist 1 (HY-151481) is a FXR antagonist.
    β-FXR antagonist 1
  • HY-15414AR
    Vortioxetine hydrobromide (Standard) 960203-27-4 99.59%
    Vortioxetine (hydrobromide) (Standard) is the analytical standard of Vortioxetine (hydrobromide). This product is intended for research and analytical applications. Vortioxetine (Lu AA 21004) hydrobromide is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of 5-hydroxytryptamine transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial 5-HT1B agonist (Ki: 15 nM, 33 nM).
    Vortioxetine hydrobromide (Standard)
  • HY-158821A
    ISTH0036 sodium
    ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
    ISTH0036 sodium
  • HY-161743A
    PBA-1105 TFA 99.58%
    PBA-1105 TFA is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1105 TFA selectively binds to exposed hydrophobic regions of misfolded proteins, facilitating their degradation via the autophagic pathway. PBA-1105 TFA increases the autophagic flux of Ub-conjugated aggregates.
    PBA-1105 TFA
  • HY-17390AR
    Loxapine succinate (Standard) 27833-64-3 99.92%
    Loxapine (succinate) (Standard) is the analytical standard of Loxapine (succinate). This product is intended for research and analytical applications. Loxapine succinate is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent. Loxapine can also suppresses bacterial efflux pump activity and inhibit intracellular multiple-antibiotic-resistant Salmonella enterica serovar Typhimurium in macrophages.
    Loxapine succinate (Standard)
  • HY-17412S1
    Minocycline-d6 sulfate
    Minocycline-d6 sulfate is deuterated labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline-d6 sulfate
Cat. No. Product Name / Synonyms Application Reactivity